CordenPharma Enters Oligonucleotide API Manufacturing Market to Further Strengthen CDMO Offering
CordenPharma recently announced its expansion into the oligonucleotide Active Pharmaceutical Ingredient (API) development and manufacturing market.
Dr. Christian Ewers, Vice President Operations, CordenPharma, indicated the investment has already been initiated in CordenPharma Colorado (Boulder, CO), and is expected to be complete before the end of the year. CordenPharma is in a unique position to enter this market segment due to its strong presence in Peptides, Lipids & Carbohydrates for APIs and Drug Products. The expansion will broaden CordenPharma’s fully integrated service offering, which has proven to be a very successful model in addressing customer time and cost-saving needs by streamlining the manufacturing process.
“Based on the rich pipeline in the growing oligonucleotide field, this is a very logical move for CordenPharma within our current API and Drug Product manufacturing offerings. The expansion into the oligonucleotide market is a synergistic complement to our outstanding experience in the manufacture of synthetic lipids, peptides, and carbohydrates, which are also used in oligonucleotide drug delivery,” said Dr. Mimoun Ayoub, Director, Peptides, Lipids, Carbohydrates & Injectables Platforms, CordenPharma International.
“We are excited to start the initial phase to add oligonucleotide development and manufacturing to our existing broad capacities in peptides and highly potent APIs. Our strategy includes further investment down the road to accommodate much larger oligonucleotide volumes going forward. This will in turn allow us to better serve our customers’ needs for these innovative APIs,” added Brian McCudden, President of CordenPharma Colorado.
CordenPharma International, a pharmaceutical brand of International Chemical Investors Group (ICIG), is a full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Drug Products, and associated Packaging Services. Through a network of fully inspected cGMP facilities across Europe and the US organized under five technology platforms – Peptides, Lipids & Carbohydrates, Injectables, Highly Potent & Oncology, Small Molecules, Antibiotics – CordenPharma experts translate complex ideas at any stage of development into high-value products. For more information, visit www.cordenpharma.com.
Total Page Views: 2112